Nadir Yona, Brenner Benjamin
Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Health Care Campus, Haifa, Israel.
Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Health Care Campus, Haifa, Israel.
Thromb Res. 2014 May;133 Suppl 2:S90-4. doi: 10.1016/S0049-3848(14)50015-1.
Heparanase is an endo-β-D-glucuronidase that is capable of cleaving heparan sulfate side chains of heparan sulfate proteoglycans on cell surfaces and the extracellular matrix, activity that is strongly implicated in tumor metastasis and angiogenesis. Apart of its well characterized enzymatic activity, heparanase was noted to exert also enzymatic-independent functions. Among these are the up-regulation of vascular endothelial growth factor (VEGF)-A, VEGF-C and activation of intra-cellular signaling involved in cell survival and proliferation. We had earlier demonstrated that heparanase may also affect the hemostatic system in a non-enzymatic manner. We had shown that heparanase up-regulated the expression of the blood coagulation initiator- tissue factor (TF) and interacted with the tissue factor pathway inhibitor (TFPI) on the cell surface membrane of endothelial and tumor cells, leading to dissociation of TFPI and resulting in increased cell surface coagulation activity. Moreover, we have demonstrated that heparanase directly enhanced TF activity which led to increased factor Xa production and subsequent activation of the coagulation system. Taking into account the prometastatic, pro-angiogenic and pro-coagulant functions of heparanase, over-expression in human malignancies and abundance in platelets, implies that heparanase is potentially a good target for cancer therapy.
乙酰肝素酶是一种内切-β-D-葡糖醛酸酶,能够切割细胞表面和细胞外基质上硫酸乙酰肝素蛋白聚糖的硫酸乙酰肝素侧链,这种活性与肿瘤转移和血管生成密切相关。除了其已被充分表征的酶活性外,人们还注意到乙酰肝素酶也发挥非酶依赖性功能。其中包括上调血管内皮生长因子(VEGF)-A、VEGF-C以及激活参与细胞存活和增殖的细胞内信号传导。我们之前已经证明,乙酰肝素酶也可能以非酶方式影响止血系统。我们已经表明,乙酰肝素酶上调凝血启动因子——组织因子(TF)的表达,并在内皮细胞和肿瘤细胞的细胞膜上与组织因子途径抑制剂(TFPI)相互作用,导致TFPI解离,从而增加细胞表面凝血活性。此外,我们已经证明,乙酰肝素酶直接增强TF活性,导致因子Xa生成增加,随后激活凝血系统。考虑到乙酰肝素酶的促转移、促血管生成和促凝血功能,其在人类恶性肿瘤中的过表达以及在血小板中的丰富含量,意味着乙酰肝素酶可能是癌症治疗的一个良好靶点。